The company has purchased single share at an amount of NIS1.405 ($0.36).
The acquired shares represent all the shares of Teva in Proteologics and also represent nearly 31.35% of Proteologics issued and outstanding share capital.
Proteologics is a public traded company listed on the Tel Aviv Stock Exchange.
XTL focuses on late stage clinical development of drugs to treat multiple myeloma, schizophrenia and hepatitis C.